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Summary Whether women receive the same medical care for COPD as men and if
they are at risk of different outcomes as a result, is not known. The Confronting
COPD International Survey was performed in the USA, Canada, France, Italy,
Germany, The Netherlands, Spain and the UK in 2000 with 3265 COPD participants.
Forty-one per cent were women; mean age in women and men was 61.2 (SD 10.5) and
64.4 (11.0) years, mean pack-years of smoking 36 (29) and 46 (35) years,
respectively. After adjusting for age, pack-years, country and severe dyspnea
(MRC scores 5 and 4), women were less likely to have had spirometry (OR 0.84, 95%
C.I. 0.72–0.98) but more likely to get smoking cessation advice (OR 1.57, 1.33–1.86).
Despite significantly lower pack-years of smoking, women were more likely to
report severe dyspnea than men (OR 1.30, 1.10–1.54), with similar cough (OR 1.08,
0.92–1.27) and less sputum (OR 0.84, 0.72–0.98). There were no differences in the
risk of hospitalisation or emergency room visit. This study indicates that gender
differences in COPD care and outcomes exist.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Historically chronic obstructive lung disease (COPD)
has been associated with elderly, male smokers,
but recent evidence indicates that in some coun-
tries, smoking rates in women now approaches that
in men, and in the USA and Denmark, the number of
deaths from COPD in women has now overtaken
that in men.1 In the UK this event is forecast to
occur in 2008.2 However, due to the traditional
view that COPD is a male disease, it is possible that
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symptoms of COPD may not be the same as that of
men. Indeed, Chapman et al.3 have shown in a
random sample of 192 primary-care physicians
using a hypothetical case presentation and struc-
tured interview, that there exists a bias towards a
COPD diagnosis in men, particularly when spirome-
try is not part of the diagnosis. This may expose
women to lack of appropriate diagnostic proce-
dures and as a result less optimal care, as has been
evident in cardiovascular disease.4–6
Once diagnosis has been made, it is not clear
whether women are then managed differently to
men. Women generally more frequently report
severe symptoms than men, particularly dyspnea7,8
and report a lower quality of life for the same level
of lung function.9 Whether this is due to sub-
optimal management or gender differences in
subjective assessment of disease is not understood.
Sub-optimal management would be defined as
having less or inappropriate medication and lack
of advice regarding COPD, its causes and daily
management. Previous literature in cardiovascular
disease suggests that women may not receive such
early aggressive therapy as men and other litera-
ture suggests females have less access to steroids in
respiratory disease.6,10 Thus, a bias in care provi-
sion for women could be expected to result in
greater number and intensity of symptoms and
hospitalisation than men.
To our knowledge it has never been reported if
women receive the same care as men from the
physician they see most frequently for COPD. This
study reports on any differences between women
and men for symptoms, prescribed medication
and hospitalisation. This study also investigates
patient satisfaction with care to assess any gender
differences.
Methods
The design and methodology of the Confronting
COPD Survey has been described elsewhere.8 In
brief, the study was carried out between August
2000 and January 2001 in the USA, Canada, France,
Italy, Germany, The Netherlands, Spain and the UK.
From a total of 201,921 households screened by
random-digit dialling, 3265 subjects with a re-
ported physician diagnosis of COPD, chronic bron-
chitis or emphysema, or with symptoms of chronic
bronchitis (defined as persistent cough with sputum
from the chest for the last two years or more) were
identified and interviewed. All patients were at
least 45 years old and had a cumulative cigarette
consumption of at least 10 pack-years. The survey
questionnaire was based on the American Thoracic
Society questionnaire with details that have been
described before.8 Questions included symptom
severity, hospitalisation, emergency room visits,
activity limitations due to COPD and use of
respiratory therapy. The Medical Research Council
(MRC) dyspnea scale, modified according to Bestall
et al.11 was incorporated into the questionnaire
and ranged in score from 5–0: 5 ‘‘too breathless to
leave the house’’; 4 ‘‘have to stop for breath every
few minutes when walking even on level ground’’; 3
‘‘have to stop even when walking at my own pace
or walk slower than most people of my age’’; 2 ‘‘get
breathless when hurrying on level ground or
walking on a slight incline’’; 1 ‘‘only get breathless
after strenuous exercise’’; 0 ‘‘none of these’’. In
this study, severe dyspnea was defined by levels 5
and 4 from the scale. Cumulative cigarette con-
sumption in pack-years was calculated on the basis
of the number of cigarettes smoked per day and
number of years of daily smoking. The English
version of the questionnaire was translated and
back translated into Dutch, French, German, Italian
and Spanish with the help of translators experi-
enced in health surveys. The interviews were
conducted in the native language of the respondent
by experienced interviewers.
The sample was stratified by region within each
country and sampled proportionally. In these ana-
lyses an unweighted sample was used. Percentage
variables were compared using w2 test, a P-value
below 0.05 being considered statistically significant.
Logistic regression was performed to test the
association between dependent variables related
to diagnostic procedures, symptoms, provision of
inhaled steroid and hospitalisation, with gender as
an independent variable. All models were addition-
ally adjusted for age, pack-years of smoking, country
and dyspnea severity (as a marker of disease
severity). Results are given as crude odds ratios
and adjusted odds ratios with 95% confidence limits.
Results
Table 1 shows that 41% of the sample were women
and on average women were slightly younger than
men and had significantly lower pack-years of
smoking. More women than men were represented
in the USA (55.3%), Canada (55.1%) and the UK
(51.2%). Based on self-report, only 34% of women
and 39% of men reported ever having a spirometry
test and only 37% of women and 28% of men
reported ever receiving anti-smoking advice. Twenty
nine per cent of women and 24% of males reported
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severe dyspnea (Po0:05), 71% of women and 66% of
men reported symptoms of cough and 62% of both
men and women reported sputum.
Table 2 shows the association between gender
and the dependent variables related to diagnosis,
care, symptoms and hospitalisation. It can be seen
that fewer women are given spirometry than men
when controlling for the independent variables of
age, pack-years, MRC dyspnea severity and country
(adjusted odds ratio (OR) 0.84 95% CI 0.72, 0.98).
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Table 1 Patient demographics, symptoms and treatment variables.
Men Women
N % N %
Patients 1937 59 1328 41
AgeFmean (SD) 64.4 (11.0) 61.2 (10.5)
Pack-years-mean (SD) 46.6 (35.1) 36.9 (29.6)n
Spirometry ever 747 39 453 34n
Anti-smoking advice ever 535 28 488 37n
Sputum (Xfew days per week) 1207 62 822 62
Severe dyspnea (MRC 4&5) 467 24 382 29n
Cough(Xfew days per week) 1274 66 943 71
Hospitalisation (in last year) 263 14 150 11
Emergency room visit (in last year) 235 12 152 11
ICS use (now or in last year) 409 21 315 24
Inhaler training ever 1178 61 888 67n
nPo0:05:






Women 0.83 (0.71,0.95) 0.84 (0.72,0.98)
Anti smoking advice ever
Women 1.52 (1.31,1.77) 1.57 (1.33,1.86)
SputumXfew days per week (for any 3 month period in the last
year)
Women 0.98 (0.85,1.14) 0.84 (0.72,0.98)
Severe dyspnea (MRC scale 4/5)
Women 1.27 (1.09,1.49) 1.30 (1.10,1.54)
CoughXfew days per week (for any 3 month period in the last
year)
Women 1.28 (1.10,1.48) 1.08 (0.92, 1.27)
Hospitalisation in the last year
Women 0.81 (0.65,1.00) 0.81 (0.64,1.03)
Emergency Room visit in the last year
Women 0.94 (0.75,1.16) 0.80 (0.63,1.01)
ICS use now or in past year
Women 1.16 (0.98,1.37) 1.01 (0.84,1.21)
Inhaler training ever
Women 1.30 (1.12,1.51) 1.03 (0.88,1.22)
Each model was adjusted for age, pack-years of smoking, country and dyspnea severity.
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More women receive anti-smoking advice than men
when adjusting for the same variables (OR 1.57 95%
CI 1.33, 1.86). Women were less likely to have
sputum (OR 0.84 95% CI 0.72, 0.98) and more likely
to suffer from severe dyspnea (OR 1.30 95% CI 1.10,
1.54) than men but there was no difference in risk
of cough between sexes after adjusting for
the independent variables. Figure 1 illustrates
the differences between men and women for
subjective dyspnea assessment. Both sexes re-
ported more frequently mild dyspnea (MRC scores
1 and 2) than severe dyspnea, but men were
significantly more likely to have mild dyspnea (MRC
score 1, men 23.8% vs. women 20.1%, P ¼ 0:006)
and women to have more severe dyspnea (MRC
score 5, men 5.5% vs. women 7.8%, P ¼ 0:005).
Hospitalisation and emergency room visit were
not significantly different between men and women
nor was the likelihood of being treated with an
inhaled corticosteroid or being trained with an
inhaler.
Table 3 illustrates patient satisfaction with care
and shows that there were no significant differ-
ences between men and women in their views of
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Figure 1
Table 3 Patient satisfaction with treatment by gender (patients who strongly agree/agree with the statement).
Men % Women %
Satisfied with doctors management and treatment 82.5 83.2
The doctor’s advice helped improve ability to manage respiratory symptoms 66.3 69.3
The doctor is genuinely concerned to help me 88.8 88.0
My doctor is very knowledgable about my condition and its treatment 83.2 82.3
My doctor really involves me in decisions about my treatment 73.8 75.2
My doctor thinks my condition is my fault 42.3 41.4
My doctor does not think he/she can do anything to relieve my symptoms 30.1 27.8
Doctors do not understand what it is like to suffer from my condition 26.3 27.4
There were no significant differences between males and females (P 0.05) for any of the questions.
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physician care. The majority of patients were
satisfied or very satisfied with their care and felt
that their clinicians were doing their best to be
supportive and had good knowledge of COPD.
Whilst approximately 40% of men and women
felt that the doctor considered their COPD to be
self-inflicted, only 30% of men and 27% of women
reported their clinician as being unable to help
them control their symptoms.
Discussion
This study shows that, despite a higher prevalence
of some reported symptoms by women, in this
population with COPD spirometry was less applied
in women than in men in 2000. Conversely, women
receive advice on smoking cessation more fre-
quently than men. Women were more likely
to suffer from severe dyspnea and equally likely
to have cough symptoms, despite being younger
and having significantly less pack-years of smoking.
Factors associated with disease control such as
hospitalisation, emergency room visit and prescrip-
tion of a steroid were not different between
women and men. In three countries women in this
survey were more highly represented than men, but
this is more likely due to a response bias favouring
women in these countries, than being actually
representative of disease burden at the time of
the survey.
Guidelines for COPD recommend that spirometry
is used as a diagnostic tool in the evaluation of
patients presenting with symptoms associated with
COPD.12 This is both to confirm obstructive airways
disease and to differentiate between asthma and
COPD. In this population, sampled from countries
throughout Europe and North America, fewer than
40% of patients reported having had spirometry. For
women this figure falls to 34%. Patients in this
sample have been reported previously as receiving
most of their care from either general practice
(62.4%) or from other care givers (15%).8 To date, it
has been recognised that use of spirometry in
general practice remains low which may hinder
proper diagnostics and especially the differential
diagnosis between COPD and asthma.13–15 Why
women should receive even less spirometric testing
than men is difficult to evaluate but could be
related to the bias that COPD is still considered a
male disease, which was historically the case. This
type of gender bias is well illustrated in cardiovas-
cular disease where, in a study of patients who had
suffered an acute myocardial infarction, women of
all ages were less likely to be given diagnostic
catheterisation, aspirin within 24 h after arrival at
hospital, or thrombolytic therapy within 60min
compared to men, despite being ideal candidates
for such interventions.6 This data is supported by
other studies showing that women hospitalised for
coronary heart disease undergo fewer major
diagnostic and therapeutic procedures than
men.4,5 The literature on under use of diagnostic
procedures for women with cardiovascular disease
has been attributed to the fact that the disease,
like COPD, has been traditionally associated with
males, particularly in the elderly, where gender
bias in diagnostic and therapeutic procedures is
the most pronounced.16 Another reason for under
use of spirometry in women is that clinicians
may make assumptions that women presenting
with symptoms primarily of cough and dyspnea,
may in fact have asthma, a hypothesis supported
by the study of Chapman et al.3 They found that
using spirometry as part of the diagnostic proce-
dure removed gender bias in labelling patients as
having COPD. It is therefore unfortunate that
spirometry is not being more widely used to
diagnose COPD.
The majority of men and women in this popula-
tion had not received advice from their clinician on
the most appropriate methods of smoking cessa-
tion, despite this factor constituting a cornerstone
of the guidelines with regard to the treatment and
care of patients with COPD.12 Interestingly, women
had a greater likelihood than men to receive this
advice. This could in part be due to biased
reporting by men on being advised about smoking
cessation. It may also indicate that clinicians are
aware of literature supporting the fact that women
find it harder to give up smoking and thus encourage
and support quit attempts with advice.17,18
Despite being younger and with significantly less
pack-years of smoking, women reported more
severe dyspnea than males, suggestive of more
severe disease in women. This has been previously
shown in other studies in COPD7 and additionally in
asthma.19 Whether women in this population had
relatively more severe airway obstruction than
men, or whether their subjective view of dyspnea
was actually different from men is impossible to
assess in this observational study. A reason why
women in this sample may have more severe
dyspnea, suggestive of more severe disease, de-
spite lower levels of smoking, could be related to
the fact that the prevalence of COPD symptoms is
higher in subjects with airway hyperresponsiveness
(AHR) than those without AHR.20 Women have been
observed to have greater risk of AHR than men,
possibly associated with smoking.21 Alternatively it
is possible that there is a selection bias in the
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sample, women needing to have more severe
symptoms than men, to achieve a diagnosis of
COPD. Women in this study also reported the same
risk of cough as men despite lower pack-years of
smoking. This fact combined with greater severity
of dyspnea would, however, suggest that women
are more at risk from the effects of smoking. A
recently published paper also supports the finding
that women are likely to suffer more symptoms
with a similar smoking burden.22 Previous literature
has shown that smoking has a greater impact upon
the health of women as they have a higher risk of
being admitted to hospital for COPD, even after
adjusting for pack-years of smoking.23 Further-
more, some literature has shown that decline in
FEV1 is steeper in women than men for the same
smoking exposure24,25 and that lung growth is
reduced due to smoking exposure during adoles-
cence.26 It is known that the composition of
lymphocyte subsets in the lower respiratory tract
changes with age in women but not men and it has
been suggested that this is the reason why women
are more predisposed to certain symptoms such as
cough.27 This, combined with the detrimental
effects of cigarette smoke, may partly explain the
higher rate of severe dyspnea and cough observed
in female smokers than in male smokers here and
elsewhere. However, there are conflicting reports
with regard to tobacco smoking and lung function in
men and women, in part due to differing metho-
dology; this area therefore warrants further in-
vestigation.24,28
Rates of hospitalisation and emergency room
visit were relatively high in this population as
compared to other epidemiological studies such as
the Copenhagen City Health Study where the
hospitalisation rate was only 2.4% and the Glostrup
Population Study where it was 0.5%.23 However, in
the Danish studies the populations were probably
milder and the hospitalisation episodes were taken
from hospital records. In this study, self-reporting
of hospital and emergency room visits may have
been vulnerable to exaggeration, as patients may
have confused visits for other co-morbidities in
their estimation.
To our knowledge this is the first study
to investigate a gender effect on satisfaction with
medical care. The results show that women
and men are generally satisfied with their care
and felt that the clinician was knowledgeable about
COPD. The results of this survey, however, do
not necessarily support the patients’ views regard-
ing their clinicians’ knowledge of COPD diagnosis
and care, as they raise questions regarding
knowledge and application of guideline recommen-
dations.
Conclusion
This study shows that of the minority of patients
who are given spirometric tests, women receive
less than men. Advice regarding smoking cessation
was only given to a minority of patients with COPD,
with more given to women. For less pack-years of
smoking women were at greater risk of severe
dyspnea than men and at the same risk of cough.
Women did not differ from males in their views of
COPD care provision and satisfaction with care.
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